Voyager Therapeutics (STU:VT6) Gross-Profit-to-Asset % : 19.05% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Voyager Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Voyager Therapeutics's annualized Gross Profit for the quarter that ended in Mar. 2024 was €71.8 Mil. Voyager Therapeutics's average Total Assets over the quarter that ended in Mar. 2024 was €377.1 Mil. Therefore, Voyager Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 19.05%.

Voyager Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Voyager Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Gross-Profit-to-Asset % Chart

Voyager Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

39.57

52.65

17.13

23.99

97.03

Voyager Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															242.05	5.92	6.10	110.44	19.05

Competitive Comparison of Voyager Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Voyager Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Gross-Profit-to-Asset % falls into.

Voyager Therapeutics Gross-Profit-to-Asset % Calculation

Voyager Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	229.257	/	( (150.432	+	322.125)	/ 2 )
	=	229.257	/	236.2785
	=	97.03 %

Voyager Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	71.82	/	( (322.125	+	432.025)	/ 2 )
	=	71.82	/	377.075
	=	19.05 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Voyager Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyager Therapeutics (STU:VT6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

VYGR:USA VT6:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (STU:VT6) Headlines

No Headlines